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Prestroke Cognitive Function and Cerebrovascular Disease
If They Interact, It May Not Be Through Symptomatic Stroke
Mike O’Sullivan, PhD
See related article, pages 36–41.
In this issue of Stroke, Reitz and coworkers explore the linkbetween incident stroke and dementia in data from the
Rotterdam Study.1 The emphasis on incident stroke is impor-
tant: previous studies to address this question have recruited
patients at the time of stroke so that prestroke cognitive status
has been inferred rather than measured directly.2,3 Therefore,
this is the first truly prospective data to assess the relationship
between prestroke cognitive decline, stroke and subsequent
dementia. Incident stroke led to a doubling of dementia risk
over a mean follow-up time of 3.9 years. An approximate
doubling of risk has also been found in other cohorts like
those from Rochester and Framingham, so this study provides
important confirmation of this size of effect.2
Much interest has surrounded the possible mechanisms of
this doubling of risk: does stroke have an independent effect
or does it accelerate some pre-existing process in the brain?
More specifically, does stroke accelerate a pre-existing neu-
rodegenerative process like coincident Alzheimer disease
(AD)—a synergy that would fit with the strong epidemiolog-
ical evidence of the link between vascular risk factors and
AD.4 In the absence of good biomarkers to diagnose neuro-
degenerative disease at the time of stroke, one way to assess
this question indirectly is to infer some pre-existing process
from prestroke cognitive decline.
The most important and interesting finding of the study is
that no interaction was seen between prestroke cognitive
function and stroke on the risk of subsequent dementia.
Readers should not be confused about what this means. This
does not mean that prestroke cognitive impairment is unim-
portant and does not contradict studies showing that those
with prestroke cognitive impairment have a higher risk of
developing dementia.3 Given that the concept of dementia is
based on an arbitrary cognitive threshold it is not surprising
that cognitive status, defining the distance a subject has to fall
to meet the criteria, predicts dementia at some fixed point in
the future. Nor is it that surprising that having a stroke
increases this probability. The interesting question—because
it may reveal something about the mechanisms that unfold to
produce dementia after stroke—are whether these factors
interact. The results presented by Reitz et al suggest that they
do not, at least within the context of this study. Incident stroke
led to a doubling of risk regardless of prestroke cognitive
status. Furthermore, the impact of stroke was the same in
those at genetic risk for AD (through possession of the ApoE
4 allele) as in those without this factor, and did not seem to
vary according to risk factor profile. Of course those with
cognitive decline or with certain risk factors will have a
higher baseline dementia risk, but the impact of stroke seems
to be a uniform doubling of risk across groups.
The strengths of the study are accurately described by the
authors. It is large, prospective and the completeness of
follow-up and case ascertainment are good. One advantage of
the truly prospective nature is that the authors were able to
assess the slope of prestroke cognitive change as well as the
level immediately before stroke. This is important as both
level and rate of change will determine whether a subject will
meet a threshold for dementia at some point in the future.
However, one limitation is that assessment of cognition was
restricted to the MMSE. The nonlinear nature of this scale,
lack of sensitivity to change in some cognitive domains, and
vulnerability to practice effects means that the estimation of
slope of cognitive change is likely to have been coarse. If
anything, however, the use of the MMSE, which is heavily
focused toward the cognitive deficits of AD, may have biased
the study toward testing an interaction between stroke and
prestroke AD, which many would see as the more interesting
question. It was not possible to assess this question directly
by calculating separate hazard ratios for AD and vascular
dementia. Because this distinction would have been based on
criteria rather than pathology, incident stroke would have
biased the diagnosis of subtype toward vascular dementia,
leading to an inevitable circularity. Therefore, the interaction
between stroke and prestroke processes in specific dementia
subtypes remains an open question.
One limit to the scope of these results that should not be
forgotten is that this was a study of symptomatic stroke. The
Rotterdam Study has also shown us that silent strokes are
common, indeed more common than symptomatic events,5
and cognitively important.6 Symptomatic strokes will be
found for the most part in the sensorimotor systems, where
interaction with an ongoing neurodegenerative process may
be least likely. Put differently, symptomatic stroke and
processes of prestroke cognitive decline may be kept apart by
their different spatial locations.
There is also more to cerebrovascular disease than stroke.
Aside from lacunar infarction, the cardinal manifestations of
small-vessel disease include diffuse white matter lesions,
which when confluent are described as leukoaraiosis. Many
of the risk factors shared by cerebrovascular disease and AD
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are also shared by acute stroke and these more insidious and
progressive manifestations of cerebrovascular disease.
Chronic hypoperfusion, not sufficient to induce complete
infarction, has long been put forward as a mechanism for
diffuse white matter lesions, and recent pathological evidence
from the UK MRC Cognitive Function and Ageing Study
supports this by showing that inducible factors produced in
response to ischemia, such as hypoxia-inducible factors 1
and 2 (HIF1 and HIF2), are elevated in deep white matter
lesions in older adults.7 Interestingly, evidence is emerging in
rats and in vitro models that chronic hypoperfusion may drive
the pathological cascade of AD8 via these factors. Chronic
hypoperfusion promotes the accumulation of A, and this
effect may be mediated by HIF1, which promotes expres-
sion of the -secretase enzyme, funnelling more amyloid
precursor protein down the amyloidogenic pathway.9 So there
is a molecular rationale to suggest that interaction between
cerebrovascular disease and AD can be mediated by diffuse
white matter lesions. Furthermore, this is only one of a
number of potential mechanisms that could account for the
relationship between white matter lesions and circulating A
found in a range of subjects including those with AD, mild
cognitive impairment and community-dwelling carriers of the
ApoE 4 allele.10,11
Understanding the broader impact of cerebrovascular dis-
ease and stroke on cognitive function and the burden of
dementia is a major research goal. This study suggests that
the impact of symptomatic stroke on dementia risk is inde-
pendent of prestroke cognitive status and other baseline
characteristics. Further studies with detailed imaging will
help to determine whether silent infarcts, or infarcts in
specific locations, interact with pre-existing processes in the
brain. Furthermore, in looking for interactions with AD,
nonstroke manifestations of cerebrovascular disease, like
diffuse white matter lesions, are also promising candidates. In
the meantime, physicians should continue to see poststroke
dementia as an important target for secondary prevention and
bear in mind the results of trials like PROGRESS12 and
Syst-Eur,13 though new strategies and more data are needed.
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